Semaglutide and Heart Health: What the Research Shows

How Semaglutide Works in the Body

Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1). GLP-1 is a hormone naturally released by the gut after eating. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and signals the brain to reduce appetite. Semaglutide mimics this hormone with a much longer duration of action — lasting approximately one week after a single injection.

Beyond glucose and appetite control, GLP-1 receptors are found throughout the cardiovascular system — in the heart muscle, blood vessels, and kidneys. This distribution is why researchers suspected early on that semaglutide might have direct cardiovascular benefits beyond simply lowering blood sugar or body weight.

The SELECT Trial: A Landmark Cardiovascular Study

Published in the New England Journal of Medicine in November 2023, the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial enrolled 17,604 adults across 41 countries. Key details:

• Participants had pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
• All participants had BMI ≥ 27
• None had diabetes at enrollment — a critical distinction
• Participants received either weekly semaglutide 2.4 mg (Wegovy dose) or placebo for up to 5 years

The results were striking:

• 20% reduction in the primary endpoint: major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke
• The benefit was consistent across all pre-specified subgroups
• The cardiovascular benefit appeared independent of the degree of weight loss — suggesting semaglutide may have direct cardioprotective mechanisms beyond fat reduction

These findings led the FDA to approve Wegovy in March 2024 specifically for cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease — making it the first weight loss drug approved for a cardiovascular indication.

How Semaglutide Protects the Heart

Researchers have proposed several mechanisms by which semaglutide benefits the cardiovascular system:

• Reduced inflammation: Semaglutide lowers levels of C-reactive protein (CRP) and other inflammatory markers. Chronic low-grade inflammation is a major driver of atherosclerosis (arterial plaque buildup).
• Blood pressure reduction: Clinical trials consistently show a 3–6 mmHg reduction in systolic blood pressure, even after accounting for weight loss.
• Improved lipid profile: Semaglutide modestly reduces LDL cholesterol and triglycerides while raising HDL cholesterol.
• Kidney protection: The FLOW trial (2024) showed that semaglutide reduced the risk of kidney disease progression and cardiovascular death in patients with type 2 diabetes and chronic kidney disease by 24%.
• Direct cardiac effects: Animal studies suggest semaglutide may reduce cardiac fibrosis and improve heart function independent of weight loss, though this is still being studied in humans.

Semaglutide and Blood Pressure

High blood pressure (hypertension) affects nearly half of American adults and is a leading risk factor for heart attack and stroke. Multiple semaglutide trials — including STEP 1 through STEP 4 — showed consistent reductions in systolic blood pressure of 3–6 mmHg on average. While this may seem modest, population-level data suggests that a 5 mmHg reduction in systolic blood pressure reduces stroke risk by about 14% and coronary artery disease risk by about 9%.

For patients already on blood pressure medications, this means semaglutide may allow dose reductions over time — though any changes should be made under physician supervision.

What About Heart Rate?

One consistent finding across GLP-1 trials is a modest increase in resting heart rate — typically 2–4 beats per minute. The clinical significance of this is debated. In the LEADER trial (liraglutide, a related GLP-1 drug), the heart rate increase was associated with a small increase in heart failure hospitalizations in a subgroup of high-risk patients. However, the SELECT trial with semaglutide showed a net cardiovascular benefit despite this effect.

Patients with pre-existing arrhythmias or conditions like atrial fibrillation should discuss this with their physician before starting semaglutide.

Is Semaglutide Safe for People With Heart Disease?

Based on available evidence, semaglutide appears not just safe but actively beneficial for most people with established cardiovascular disease who meet eligibility criteria. The SELECT trial specifically studied this population — people with prior heart attacks or strokes — and showed clear benefit.

That said, there are important caveats:

• Pancreatitis history: Patients with a history of pancreatitis should avoid GLP-1 medications.
• Medullary thyroid carcinoma: Semaglutide carries a boxed warning for thyroid C-cell tumors based on animal studies; it is contraindicated in patients with personal or family history of medullary thyroid cancer or MEN2.
• Severe heart failure: Data in patients with NYHA Class IV heart failure is limited; discuss with a cardiologist.
• Diabetic medication interactions: In patients with diabetes, semaglutide can cause hypoglycemia when combined with sulfonylureas or insulin — dose adjustments may be needed.

The Bottom Line

Semaglutide is no longer just a weight loss or diabetes drug — it is now a cardiovascular medicine with compelling evidence to match. The SELECT trial demonstrated a 20% reduction in heart attacks, strokes, and cardiovascular deaths in people with obesity and pre-existing heart disease. Combined with its effects on blood pressure, inflammation, and kidney function, semaglutide represents one of the most significant advances in cardiovascular preventive medicine in a generation.

If you have obesity and cardiovascular disease, or significant cardiovascular risk factors, semaglutide may now qualify as a medically necessary treatment — not just a lifestyle option. Talk to a physician about whether you're a candidate and whether insurance coverage applies to your situation.